EVENT / PUBLIC SOURCE RECORD
Healthcare Investment Access (HIA) Programme
- The page dates the 2025–26 cohort Nov 25, 2025–Mar 26, 2026, based in New York. HIA is described as an investment-readiness programme for Nordic healthcare ventures seeking international growth, especially access to U.S. capital markets. It combines expert assessment, mentoring, workshops, and exposure to investors and other stakeholders in Europe and the United States.
- Programme steps: a 360-degree clinical, commercial, regulatory, and financing review; tailored mentoring on company story/value proposition, investor materials, priorities, milestones, and U.S./European investor expectations; and workshops on pitching, competitive positioning, investor-ready data, and market-entry alignment. Exposure opportunities include DNB Carnegie Nordic Healthcare Conference in Oslo, European Healthcare Investor Forum in Zurich, and Nordic-American Healthcare Conference in New York.
- The page says seven companies were selected but displays eight names: Akigai, DoMore Diagnostics, ImmunoQT, Node Pharma, RAB Diagnostics, ROPCA, Thelper, and Tribune Therapeutics. Contacts: Tone Varslot Stave (Innovation Norway health/life science export initiative; tone.varslot.stave@innovasjonnorge.no) and Andreas Dirnagl (Senior Advisor, Healthcare, DNB Bank; Andreas.dirnagl@dnb.no). Partners/collaborators shown include Innovation Norway, DNB, and Oslo Cancer Cluster.
- Standard event conditions require ESG-aligned responsible conduct, compliance with the UN Guiding Principles and OECD Guidelines, and company due diligence on adverse impacts.